Disparities in care by insurance status for individuals with rheumatoid arthritis: analysis of the medical expenditure panel survey, 2006–2009

References

• Smolen JS, Aletaha D, Bijlsma JW, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1-25
   PubMed Web of Science ®Google Scholar
• Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006;55:864-72
   PubMed Web of Science ®Google Scholar
• Krishnan E, Lingala B, Bruce B, Fries JF. Disability in rheumatoid arthritis in the era of biological treatments. Ann Rheum Dis 2012;71:213-18
   PubMed Web of Science ®Google Scholar
• Shourt CA, Crowson CS, Gabriel SE, Matteson EL. Orthopedic surgery among patients with rheumatoid arthritis 1980–2007: a population-based study focused on surgery rates, sex, and mortality. J Rheumatol 2012;39:481-5
   PubMed Web of Science ®Google Scholar
• Keystone EC, Breedveld FC, van der Heijde D, et al. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol 2014;41:5-14
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Landewé R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39
   PubMed Web of Science ®Google Scholar
• Schmajuk G, Schneeweiss S, Katz JN, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007;57:928-34
   PubMed Web of Science ®Google Scholar
• Shipton D, Glazier RH, Guan J, Badley EM. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population. Med Care 2004;42:907-13
   PubMed Web of Science ®Google Scholar
• DeWitt EM, Glick HA, Albert DA, et al. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians’ prescribing behavior. Arch Intern Med 2006;166:57-63
   PubMed Web of Science ®Google Scholar
• US Department of Health & Human Services, Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS). Washington, DC. Available at: http://meps.ahrq.gov/mepsweb [Last accessed 27 June 2016]
   Google Scholar
• Ware JE, Kosinski M, Turner-Bowker DM, Gandek B. How to score version 2 of the SF-12 Health Survey (with a supplement documenting version 1). Lincoln, RI, USA: QualityMetric Incorporated, 2002
   Google Scholar
• Rasch EK, Hirsch R, Paulose-Ram R, et al. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003;48:917-26
   PubMed Web of Science ®Google Scholar
• Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Fox KM, Johnson BH, et al. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Ther 2012;34:457-67
   PubMed Web of Science ®Google Scholar
• Martin RW, McCallops K, Head AJ, et al. Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug. BMC Med Inform Decis Mak 2013;13:89
   PubMed Web of Science ®Google Scholar
• Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010;69:638-43
   PubMed Web of Science ®Google Scholar
• Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health 2008;98:1300-5
   PubMed Web of Science ®Google Scholar
• Schmajuk G, Trivedi AN, Solomon DH, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011;305:480-6
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US Medicare program. Arthritis Care Res (Hoboken) 2013;65:1743-51
   PubMedGoogle Scholar
• Yelin EH, Trupin LS, Katz PP. Impact of managed care on the use of biologic agents for rheumatoid arthritis. Arthritis Rheum 2005;53:423-30
   PubMed Web of Science ®Google Scholar
• Karaca-Mandic P, Joyce GF, Goldman DP, Laouri M. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Serv Res 2010;45(5 Pt 1):1227-50
   PubMed Web of Science ®Google Scholar
• Brunner HI, Taylor J, Britto MT, et al. Differences in disease outcomes between Medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. Arthritis Rheum 2006;55:378-84
   PubMed Web of Science ®Google Scholar
• Elrod CS, DeJong G. Determinants of utilization of physical rehabilitation services for persons with chronic and disabling conditions: an exploratory study. Arch Phys Med Rehabil 2008;89:114-20
   PubMed Web of Science ®Google Scholar
• Minden SL, Hoaglin DC, Hadden L, et al. Access to and utilization of neurologists by people with multiple sclerosis. Neurology 2008;70(13 Pt 2):1141-9
   PubMed Web of Science ®Google Scholar
• Resneck J Jr, Pletcher MJ, Lozano N. Medicare, Medicaid, and access to dermatologists: the effect of patient insurance on appointment access and wait times. J Am Acad Dermatol 2004;50:85-92
   PubMed Web of Science ®Google Scholar
• Resneck JS Jr, Isenstein A, Kimball AB. Few Medicaid and uninsured patients are accessing dermatologists. J Am Acad Dermatol 2006;55:1084-8
   PubMed Web of Science ®Google Scholar
• Deal CL, Hooker R, Harrington T, et al. The United States rheumatology workforce: supply and demand, 2005–2025. Arthritis Rheum 2007;56:722-9
   PubMed Web of Science ®Google Scholar